
Articles
-
1 week ago |
genengnews.com | Corinna Singleman |Alex Philippidis |Uduak Grace Thomas |Fay Y. Lin
Credit: Just_Super / iStock / Getty Images Plus BIO 2025 is off and running. GEN editors discuss the size and scope of the bustling conference hall and share excitement about the week’s talks and panels. News from BIO includes the announcement of Lilly’s acquisition of Verve Therapeutics. Editors discuss the implications of industry-backed therapeutics amid cautious investors and public sentiment.
-
1 week ago |
genengnews.com | Corinna Singleman
Credit: Miyako Nakamura / iStock / Getty Images Plus The proteins found in nature represent only a tiny fraction of the nearly limitless protein structures that could theoretically exist. By designing proteins de novo—from scratch—scientists can more efficiently create novel therapeutics tailored for specific biological functions. In a new study, researchers introduce an AI-driven framework that accelerates this process, moving protein design toward custom therapeutics and precision medicine.
-
2 weeks ago |
genengnews.com | Corinna Singleman
Credit: selvanegra / Getty Images Vaccinations have revolutionized healthcare, but designing them remains complex, requiring time and creativity, especially for vaccines against viruses, which are difficult to study.
-
3 weeks ago |
genengnews.com | Alex Philippidis |Fay Y. Lin |Uduak Grace Thomas |Corinna Singleman
A gene therapy clinical trial for Danon disease run by Rocket Pharmaceuticals has been suspended following the death of a patient. MIT and Recursion have released Boltz-2, an open-source tool that predicts molecular binding affinity at newfound speed and accuracy, aiming to democratize commercial drug discovery. Intellia Therapeutics saw its stock nosedive late last week after a patient in its Phase III trial of the CRISPR-based therapy experienced non-lethal liver toxicity.
-
3 weeks ago |
genengnews.com | Corinna Singleman
If you have ever experienced a cold sore, you may be one of the estimated 3.8 billion people worldwide (64%) who are infected with herpes simplex virus type 1 (HSV-1). Though the majority of people experience no or mild symptoms, HSV-1 has the ability to cause a rare, life-threatening neurological condition called HSV-1 encephalitis.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →